|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Isao_Teshirogi
|
|
gptkbp:collaboratedWith
|
gptkb:Roche
gptkb:ViiV_Healthcare
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:focus
|
infectious diseases
pain management
metabolic disorders
|
|
gptkbp:founded
|
1878
|
|
gptkbp:founder
|
Shonosuke Shionogi
|
|
gptkbp:headquarters_location
|
gptkb:Osaka,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shionogi & Co., Ltd.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
JP3347200002
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
|
|
gptkbp:netIncome
|
¥110.2 billion (2023)
|
|
gptkbp:notableProduct
|
Crestor (rosuvastatin)
Xofluza (baloxavir marboxil)
|
|
gptkbp:numberOfEmployees
|
5,553 (2023)
|
|
gptkbp:products
|
antibiotics
antiviral drugs
prescription drugs
HIV drugs
|
|
gptkbp:revenue
|
¥426.7 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4507
|
|
gptkbp:subsidiary
|
gptkb:Shionogi_Inc.
|
|
gptkbp:website
|
https://www.shionogi.com
|
|
gptkbp:bfsParent
|
gptkb:YEP-621
gptkb:塩野義製薬株式会社
gptkb:Shionogi_B.V.
gptkb:Shionogi_Inc.
|
|
gptkbp:bfsLayer
|
7
|